Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.
Authors
O'Sullivan, Eoin PAshley, David T
Davenport, Colin
Devlin, Niamh
Crowley, Rachel
Agha, Amar
Thompson, Christopher J
O'Gorman, Donal
Smith, Diarmuid
Affiliation
Department of Diabetes, Royal College of Surgeons in Ireland Medical School, Beaumont Hospital, Dublin, Ireland.Issue Date
2010-09MeSH
Biological MarkersC-Reactive Protein
Diabetes Mellitus, Type 2
Diabetic Angiopathies
Female
Humans
Inflammation
Interleukin-6
Male
Middle Aged
Osteoprotegerin
RANK Ligand
TNF-Related Apoptosis-Inducing Ligand
Metadata
Show full item recordCitation
Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. 2010, 26 (6):496-502 Diabetes Metab. Res. Rev.Journal
Diabetes/metabolism research and reviewsDOI
10.1002/dmrr.1109PubMed ID
20809534Abstract
Osteoprotegerin (OPG), receptor activator for nuclear factor kappa beta ligand (RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) are newly discovered members of the tumour necrosis factor-alpha receptor superfamily. While their role in bone metabolism is well described, their function within the vasculature is poorly understood. OPG inhibits vascular calcification in vitro and high serum levels have been demonstrated in type 2 diabetes, but serum RANKL and TRAIL and their potential correlation with well-established biomarkers of subclinical vascular inflammation such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) have not been described.Sixty-two patients with well-controlled type 2 diabetes and an age, gender and body mass index-matched group of 58 healthy individuals were recruited. Serum OPG, RANKL and TRAIL were measured using commercial enzyme-linked immunosorbent assays, as were hsCRP and IL-6.
Serum OPG, IL-6 and hsCRP levels, but not RANKL or TRAIL, were higher in patients with type 2 diabetes mellitus than in healthy controls, after adjustment for age and gender. After exclusion of diabetes patients with a history of micro- or macrovascular disease, OPG remained significantly higher in those with diabetes, but IL-6 and hsCRP levels were no longer elevated. There was a positive correlation between OPG and IL-6 in the group as a whole, but no correlation was found between RANKL or TRAIL and either hsCRP or IL-6.
OPG, but not RANKL or TRAIL, is significantly increased in type 2 diabetes. Higher OPG (but not IL-6 or hsCRP) in those without vascular disease suggests these biomarkers reflect separate pathophysiological processes in the vasculature.
Item Type
ArticleLanguage
enISSN
1520-7560ae974a485f413a2113503eed53cd6c53
10.1002/dmrr.1109
Scopus Count
Collections
Related articles
- Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
- Authors: Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z
- Issue date: 2009 Sep-Oct
- Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
- Authors: Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I
- Issue date: 2006 Jul
- Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
- Authors: Chang YH, Lin KD, He SR, Hsieh MC, Hsiao JY, Shin SJ
- Issue date: 2011 Aug
- Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
- Authors: Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA
- Issue date: 2001 Jun
- Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.
- Authors: Shin JY, Shin YG, Chung CH
- Issue date: 2006 Jul